Claudio Gasperini

List of Publications by Year
in descending order

121 papers	**6,144** citations	81900 **39** h-index	79698 **73** g-index
123 all docs	**123** docs citations	**123** times ranked	**6795** citing authors

#	Article	IF	Citations
1	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. Journal of Neurology, 2022, 269, 933-944.	3.6	10
2	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 448-450.	1.9	53
3	Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies. Journal of Neurology, 2022, 269, 1114-1120.	3.6	23
4	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsingâ€"remitting multiple sclerosis patients. Journal of Neurology, 2022, 269, 452-459.	3.6	10
5	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. Neurology, 2022, 98, .	1.1	31
6	Humoral- and T-Cellâ€"Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. Neurology, 2022, 98, .	1.1	125
7	Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies. Journal of Neurology, 2022, 269, 2275-2285.	3.6	18
8	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â€‰years. Multiple Sclerosis Journal, 2022, 28, 2137-2141.	3.0	3
9	A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis. Expert Review of Neurotherapeutics, 2022, 22, 499-511.	2.8	5
10	Shift of multiple sclerosis onset towards older age. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1137-1139.	1.9	12
11	Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642210903.	3.5	1
12	Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression. Multiple Sclerosis Journal, 2021, 27, 1391-1402.	3.0	27
13	The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. Multiple Sclerosis Journal, 2021, 27, 968-972.	3.0	3
14	Unilateral meningitis: unusual central nervous system involvement in rheumatoid arthritis. Practical Neurology, 2021, 21, 167-168.	1.1	2
15	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. European Journal of Neurology, 2021, 28, 1299-1307.	3.3	12
16	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. Journal of Clinical Psychology in Medical Settings, 2021, 28, 149-160.	1.4	17
17	Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110112.	3.5	0
18	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. NeuroImage: Clinical, 2021, 29, 102549.	2.7	20

#	Article	IF	Citations
19	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	3.5	48
20	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. NeuroImage: Clinical, 2021, 30, 102659.	2.7	3
21	Tailored Vessel-Catheter Diameter Ratio in a Direct Aspiration First-Pass Technique: Is It a Matter of Caliber?. American Journal of Neuroradiology, 2021, 42, 546-550.	2.4	6
22	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	5.3	370
23	Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization. Annals of Clinical and Translational Neurology, 2021, 8, 623-630.	3.7	14
24	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. Journal of Neurology, 2021, 268, 2922-2932.	3.6	18
25	Ozone-induced encephalopathy: A novel iatrogenic entity. European Journal of Neurology, 2021, 28, 2471-2478.	3.3	2
26	Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. European Journal of Neurology, 2021, 28, 2533-2542.	3.3	16
27	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. Journal of Neurology, 2021, 268, 3961-3968.	3.6	47
28	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86
29	Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	27
30	2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurology, The, 2021, 20, 653-670.	10.2	302
31	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. Disability and Rehabilitation, 2020, 42, 3780-3792.	1.8	17
32	Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study. Journal of Neurology, 2020, 267, 694-702.	3.6	6
33	Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial. Neurotherapeutics, 2020, 17, 704-709.	4.4	5
34	EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e876.	6.0	6
35	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. Multiple Sclerosis and Related Disorders, 2020, 45, 102394.	2.0	2
36	Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 585296.	2.4	4

#	Article	IF	Citations
37	Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. Neurotherapeutics, 2020, 17, 994-1004.	4.4	34
38	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. Journal of Neurology, 2020, 267, 3541-3554.	3.6	14
39	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nature Reviews Neurology, 2020, 16, 171-182.	10.1	150
40	Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 388-391.	1.9	14
41	Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 271-277.	1.9	29
42	Longitudinal Assessment of Multiple Sclerosis with the Brainâ€Age Paradigm. Annals of Neurology, 2020, 88, 93-105.	5.3	79
43	Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology, 2019, 93, e733-e746.	1.1	21
44	Lifespan normative data on rates of brain volume changes. Neurobiology of Aging, 2019, 81, 30-37.	3.1	40
45	CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis. Cells, 2019, 8, 575.	4.1	30
46	Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis Patients. Cells, 2019, 8, 533.	4.1	14
47	Resiquimod-Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple Sclerosis. International Journal of Molecular Sciences, 2019, 20, 2811.	4.1	3
48	â€œBetter explanationsâ€•in multiple sclerosis diagnostic workup. Neurology, 2019, 92, e2527-e2537.	1.1	44
49	How much do periventricular lesions assist in distinguishing migraine with aura from CIS?. Neurology, 2019, 92, e1739-e1744.	1.1	15
50	Unraveling treatment response in multiple sclerosis. Neurology, 2019, 92, 180-192.	1.1	88
51	Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study. Multiple Sclerosis Journal, 2019, 25, 352-360.	3.0	22
52	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nature Reviews Neurology, 2018, 14, 199-213.	10.1	157
53	FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis. Scientific Reports, 2018, 8, 3674.	3.3	42
54	Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation. Scientific Reports, 2018, 8, 1319.	3.3	41

#	Article	IF	Citations
55	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurology, The, 2018, 17, 133-142.	10.2	98
56	Deep gray matter volume loss drives disability worsening in multiple sclerosis. Annals of Neurology, 2018, 83, 210-222.	5.3	295
57	A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. Journal of Neurology, 2018, 265, 1174-1183.	3.6	23
58	Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report. Journal of Neurology, 2018, 265, 2152-2153.	3.6	7
59	Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives. Multiple Sclerosis and Demyelinating Disorders, 2018, 3, .	1.1	20
60	Fingolimod vs dimethyl fumarate in multiple sclerosis. Neurology, 2018, 91, e153-e161.	1.1	35
61	Three-Tesla MRI does not improve the diagnosis of multiple sclerosis. Neurology, 2018, 91, e249-e257.	1.1	26
62	Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 1081-1089.	2.8	20
63	Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy. Neuroepidemiology, 2017, 48, 171-178.	2.3	6
64	Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis. Molecular Neurobiology, 2017, 54, 7520-7533.	4.0	47
65	Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. Journal of Neurology, 2017, 264, 284-294.	3.6	44
66	Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients. International Journal of Molecular Sciences, 2016, 17, 2009.	4.1	25
67	Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29. Journal of the Neurological Sciences, 2016, 370, 123-131.	0.6	11
68	Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.1	98
69	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurology, The, 2016, 15, 292-303.	10.2	679
70	Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Multiple Sclerosis Journal, 2016, 22, 212-221.	3.0	56
71	Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. Journal of Neurology, 2016, 263, 751-759.	3.6	35
72	Visual pathway neurodegeneration winged by mitochondrial dysfunction. Annals of Clinical and Translational Neurology, 2015, 2, 140-150.	3.7	13

#	Article	IF	Citations
73	T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17Âin multiple sclerosis. Clinical Science, 2015, 129, 291-303.	4.3	55
74	The p38 mitogenâ€activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis. Immunology, 2015, 146, 251-263.	4.4	24
75	Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. Multiple Sclerosis Journal, 2015, 21, 1713-1722.	3.0	23
76	Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing&ndash;remitting multiple sclerosis. Therapeutics and Clinical Risk Management, 2014, 10, 229.	2.0	43
77	Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. Multiple Sclerosis Journal, 2014, 20, 1265-1268.	3.0	17
78	From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. European Neurology, 2014, 71, 233-241.	1.4	4
79	CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes. Immunology Letters, 2014, 158, 134-142.	2.5	36
80	Serum lactate as a novel potential biomarker in multiple sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1137-1143.	3.8	77
81	Effects of Bacille Calmette-GuÃ©rin after the first demyelinating event in the CNS. Neurology, 2014, 82, 41-48.	1.1	128
82	MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients. PLoS ONE, 2014, 9, e94794.	2.5	14
83	Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. Expert Opinion on Investigational Drugs, 2013, 22, 1243-1253.	4.1	10
84	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology, 2013, 80, 234-241.	1.1	53
85	A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurological Sciences, 2013, 34, 197-203.	1.9	3
86	Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology, 2013, 80, 2090-2094.	1.1	63
87	Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis. PLoS Pathogens, 2013, 9, e1003220.	4.7	132
88	Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Annals of Neurology, 2013, 73, 626-636.	5.3	83
89	Efficacy and safety of laquinimod in multiple sclerosis: current status. Therapeutic Advances in Neurological Disorders, 2013, 6, 343-352.	3.5	18
90	Advances in the treatment of relapsing&ndash;remitting multiple sclerosis &ndash; critical appraisal of fingolimod. Therapeutics and Clinical Risk Management, 2013, 9, 73.	2.0	15

#	ARTICLE	IF	CITATIONS
91	Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 64-71.	3.0	85
92	Efficacy and safety of subcutaneous interferon beta-1a in relapsing–remitting multiple sclerosis: Further outcomes from the IMPROVE study. Journal of the Neurological Sciences, 2012, 312, 97-101.	0.6	31
93	Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach. Drug Design, Development and Therapy, 2012, 6, 175.	4.3	38
94	Emerging oral drugs for relapsing–remitting multiple sclerosis. Expert Opinion on Emerging Drugs, 2011, 16, 697-712.	2.4	13
95	Impaired cortical deactivation during hand movement in the relapsing phase of multiple sclerosis: a cross-sectional and longitudinal fMRI study. Multiple Sclerosis Journal, 2011, 17, 1177-1184.	3.0	10
96	Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis. PLoS ONE, 2011, 6, e19452.	2.5	74
97	T Regulatory Cells Are Markers of Disease Activity in Multiple Sclerosis Patients. PLoS ONE, 2011, 6, e21386.	2.5	64
98	Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets. Therapeutics and Clinical Risk Management, 2010, 6, 391.	2.0	6
99	The prevalence of multiple sclerosis in central Italy. Multiple Sclerosis Journal, 2010, 16, 1432-1436.	3.0	22
100	Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 888-892.	3.0	31
101	Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study. BMC Neurology, 2009, 9, 54.	1.8	25
102	New oral drugs for multiple sclerosis. Neurological Sciences, 2009, 30, 179-183.	1.9	49
103	Emerging oral drugs for multiple sclerosis. Expert Opinion on Emerging Drugs, 2008, 13, 465-477.	2.4	17
104	Safety and Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Treated With High-Dose Subcutaneous Interferon-Beta by Rebiject Autoinjection Over a 1-Year Period. Clinical Neuropharmacology, 2008, 31, 167-172.	0.7	25
105	Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosis. Journal of Neurology, 2006, 253, 287-293.	3.6	113
106	The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. Journal of Neuroimmunology, 2005, 167, 131-137.	2.3	56
107	Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. Journal of the Neurological Sciences, 2003, 215, 3-8.	0.6	61
108	Proteolytic Balance in Patients with Multiple Sclerosis During Interferon Treatment. Journal of Interferon and Cytokine Research, 2002, 22, 689-692.	1.2	6

#	Article	IF	Citations
109	Topiramate Relieves Idiopathic and Symptomatic Trigeminal Neuralgia. Journal of Pain and Symptom Management, 2001, 21, 367-368.	1.2	56
110	Serial gadolinium-DTPA of spinal cord MRI in multiple sclerosis: triple vs. single dose. Magnetic Resonance Imaging, 2000, 18, 1183-1186.	1.8	13
111	Brain atrophy in relapsing-remitting multiple sclerosis: relationship with â€˜black holesâ€™, disease duration and clinical disability. Journal of the Neurological Sciences, 2000, 174, 85-91.	0.6	110
112	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. Journal of Neurology, 1999, 246, 97-106.	3.6	9
113	Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon Î² 1a. Journal of Neurology, 1999, 246, 443-448.	3.6	26
114	T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis. Journal of Neuroimmunology, 1999, 99, 91-96.	2.3	14
115	Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet, The, 1999, 353, 964-969.	13.7	476
116	Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. Journal of the Neurological Sciences, 1999, 168, 131-136.	0.6	61
117	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. Journal of the Neurological Sciences, 1999, 171, 130-134.	0.6	15
118	Quantitative magnetic resonance analysis in vascular dementia. Journal of Neurology, 1997, 244, 246-251.	3.6	26
119	No increase of serum autoantibodies during therapy with recombinant human interferon-Î²1a in relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica, 1997, 96, 372-374.	2.1	36
120	Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: Relationship to clinical parameters. Journal of Magnetic Resonance Imaging, 1996, 6, 580-584.	3.4	50
121	Bridging Therapies With Injectable Immunomodulatory Drugs in the Management of Multiple Sclerosis: A Delphi Survey of an Italian Expert Panel of Neurologists. Frontiers in Neurology, 0, 13, .	2.4	1